Selenium-binding Protein 1 Alters Energy Metabolism in Prostate Cancer Cells

Overview

Journal Prostate

Date 2020 Jun 9

PMID 32511787

Citations 18

Authors

Mostafa Elhodaky

Lenny K Hong

Shrinidhi Kadkol

Alan M Diamond

Affiliations

Soon will be listed here.

Abstract

Objective: The broad goal of the research described in this study was to investigate the contributions of selenium-binding protein 1 (SBP1) loss in prostate cancer development and outcome.

Methods: SBP1 levels were altered in prostate cancer cell lines and the consequences on oxygen consumption, expression of proteins associated with energy metabolism, and cellular transformation and migration were investigated. The effects of exposing cells to the SBP1 reaction products, H O and H S were also assessed. In silico analyses identified potential HNF4α binding sites within the SBP1 promoter region and this was investigated using an inhibitor specific for that transcription factor.

Results: Using in silico analyses, it was determined that the promoter region of SBP1 contains putative binding sites for the HNF4α transcription factor. The potential for HNF4α to regulate SBP1 expression was supported by data indicating that HNF4α inhibition resulted in a dose-response increase in the levels of SBP1 messenger RNA and protein, identifying HNF4α as a novel negative regulator of SBP1 expression in prostate cancer cells. The consequences of altering the levels of SBP1 were investigated by ectopically expressing SBP1 in PC-3 prostate cancer cells, where SBP1 expression attenuated anchorage-independent cellular growth and migration in culture, both properties associated with transformation. SBP1 overexpression reduced oxygen consumption in these cells and increased the activation of AMP-activated protein kinase (AMPK), a major regulator of energy homeostasis. In addition, the reaction products of SBP1, H O , and H S also activated AMPK.

Conclusions: Based on the obtained data, it is hypothesized that SBP1 negatively regulates oxidative phosphorylation (OXPHOS) in the healthy prostate cells by the production of H O and H S and consequential activation of AMPK. The reduction of SBP1 levels in prostate cancer can occur due to increased binding of HNF4α, acting as a transcriptional inhibitor to the SBP1 promoter. Consequently, there is a reduction in H O and H S-mediated signaling, inhibition of AMPK, and stimulation of OXPHOS and building blocks of biomolecules needed for tumor growth and progression. Other effects of SBP1 loss in tumor cells remain to be discovered.

Citing Articles

Selenium-Binding Protein 1 (SBP1): A New Putative Player of Stress Sensing in Plants.

Dervisi I, Koletti A, Agalou A, Haralampidis K, Flemetakis E, Roussis A Int J Mol Sci. 2024; 25(17).

PMID: 39273319 PMC: 11394908. DOI: 10.3390/ijms25179372.

Overexpression of Wheat Selenium-Binding Protein Gene Enhances Plant Growth and Grain Selenium Accumulation under Spraying Sodium Selenite.

Xiao T, Qiang J, Sun H, Luo F, Li X, Yan Y Int J Mol Sci. 2024; 25(13).

PMID: 39000115 PMC: 11240915. DOI: 10.3390/ijms25137007.

Gene expression and metabolite levels converge in the thermogenic spadix of skunk cabbage.

Tanimoto H, Umekawa Y, Takahashi H, Goto K, Ito K Plant Physiol. 2024; 195(2):1561-1585.

PMID: 38318875 PMC: 11142342. DOI: 10.1093/plphys/kiae059.

Dual targeting of HS synthesizing enzymes; cystathionine β-synthase and cystathionine γ-lyase by miR-939-5p effectively curbs triple negative breast cancer.

Nafea H, Youness R, Dawoud A, Khater N, Manie T, Abdel-Kader R Heliyon. 2023; 9(10):e21063.

PMID: 37916110 PMC: 10616356. DOI: 10.1016/j.heliyon.2023.e21063.

Selenium in Prostate Cancer: Prevention, Progression, and Treatment.

Jiang J, Chen B, Tang B, Wei Q Pharmaceuticals (Basel). 2023; 16(9).

PMID: 37765058 PMC: 10536940. DOI: 10.3390/ph16091250.

References

Pohl N, Tong C, Fang W, Bi X, Li T, Yang W . Transcriptional regulation and biological functions of selenium-binding protein 1 in colorectal cancer in vitro and in nude mouse xenografts. PLoS One. 2009; 4(11):e7774. PMC: 2774949. DOI: 10.1371/journal.pone.0007774. View

Combs Jr G, Gray W . Chemopreventive agents: selenium. Pharmacol Ther. 1998; 79(3):179-92. DOI: 10.1016/s0163-7258(98)00014-x. View

Hellmich M, Coletta C, Chao C, Szabo C . The therapeutic potential of cystathionine β-synthetase/hydrogen sulfide inhibition in cancer. Antioxid Redox Signal. 2014; 22(5):424-48. PMC: 4307161. DOI: 10.1089/ars.2014.5933. View

Gerace L . Nuclear export signals and the fast track to the cytoplasm. Cell. 1995; 82(3):341-4. DOI: 10.1016/0092-8674(95)90420-4. View

Preston M, Riis A, Ehrenstein V, Breau R, Batista J, Olumi A . Metformin use and prostate cancer risk. Eur Urol. 2014; 66(6):1012-20. DOI: 10.1016/j.eururo.2014.04.027. View

Zhao K, Li S, Wu L, Lai C, Yang G . Hydrogen sulfide represses androgen receptor transactivation by targeting at the second zinc finger module. J Biol Chem. 2014; 289(30):20824-35. PMC: 4110290. DOI: 10.1074/jbc.M114.559518. View

Lonergan P, Tindall D . Androgen receptor signaling in prostate cancer development and progression. J Carcinog. 2011; 10:20. PMC: 3162670. DOI: 10.4103/1477-3163.83937. View

Sharma N, Massie C, Ramos-Montoya A, Zecchini V, Scott H, Lamb A . The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell. 2012; 23(1):35-47. DOI: 10.1016/j.ccr.2012.11.010. View

Barfeld S, Itkonen H, Urbanucci A, Mills I . Androgen-regulated metabolism and biosynthesis in prostate cancer. Endocr Relat Cancer. 2014; 21(4):T57-66. DOI: 10.1530/ERC-13-0515. View

10.

Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P . The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008; 27(25):3576-86. DOI: 10.1038/sj.onc.1211024. View

11.

Yang M, Sytkowski A . Differential expression and androgen regulation of the human selenium-binding protein gene hSP56 in prostate cancer cells. Cancer Res. 1998; 58(14):3150-3. View

12.

Henin N, Vincent M, Gruber H, Van den Berghe G . Inhibition of fatty acid and cholesterol synthesis by stimulation of AMP-activated protein kinase. FASEB J. 1995; 9(7):541-6. DOI: 10.1096/fasebj.9.7.7737463. View

13.

Xiang X, Saha A, Wen R, Ruderman N, Luo Z . AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun. 2004; 321(1):161-7. DOI: 10.1016/j.bbrc.2004.06.133. View

14.

Schrauzer G, White D, Schneider C . Cancer mortality correlation studies--III: statistical associations with dietary selenium intakes. Bioinorg Chem. 1977; 7(1):23-31. DOI: 10.1016/s0006-3061(00)80126-x. View

15.

Foretz M, Carling D, Guichard C, Ferre P, Foufelle F . AMP-activated protein kinase inhibits the glucose-activated expression of fatty acid synthase gene in rat hepatocytes. J Biol Chem. 1998; 273(24):14767-71. DOI: 10.1074/jbc.273.24.14767. View

16.

Eidelman E, Twum-Ampofo J, Ansari J, Siddiqui M . The Metabolic Phenotype of Prostate Cancer. Front Oncol. 2017; 7:131. PMC: 5474672. DOI: 10.3389/fonc.2017.00131. View

17.

Tomlins S, Mehra R, Rhodes D, Cao X, Wang L, Dhanasekaran S . Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 2006; 39(1):41-51. DOI: 10.1038/ng1935. View

18.

Ying Q, Ansong E, Diamond A, Yang W . A Critical Role for Cysteine 57 in the Biological Functions of Selenium Binding Protein-1. Int J Mol Sci. 2015; 16(11):27599-608. PMC: 4661901. DOI: 10.3390/ijms161126043. View

19.

Ying Q, Ansong E, Diamond A, Lu Z, Yang W, Bie X . Quantitative proteomic analysis reveals that anti-cancer effects of selenium-binding protein 1 in vivo are associated with metabolic pathways. PLoS One. 2015; 10(5):e0126285. PMC: 4431778. DOI: 10.1371/journal.pone.0126285. View

20.

Singh D, Febbo P, Ross K, Jackson D, Manola J, Ladd C . Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 2002; 1(2):203-9. DOI: 10.1016/s1535-6108(02)00030-2. View